allied
academies
Virology Research Journal
Volume 1 Issue 4
Vaccines World 2017
Notes:
Page 44
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Vaccines against infectious diseases
Ivana Haluskova Balter
French Society of Immunology, France
A
vaccine is a biological preparation that improves
immunity to a particular microorganism. Accurate
diagnostic and surveillance with better understanding
of genetic and immunologic background of host specific
response and pathogen evolution drives adapted vaccine
research. AMR (antimicrobial) resistance is regarded
nowadays as a major threat to global public health. The issue
is receiving high-level political attention (G7 summit and
upcoming G20 for first time). Pandemics, drug resistance and
neglected diseases framing health as a global security issue.
WHO made a list to promote research and development
(R&D) of new antibiotics (27th Feb 2017) underlining
gram-negative bacteria. Although initially omitted from
the list, tuberculosis and latent tuberculosis represent still
a major issue to tackle. XDR tuberculosis has evolved in
several tuberculosis endemic countries to drug incurable
or programmatically incurable tuberculosis. BCG vaccine
successfully helped to interrupt transmission cycle and along
with antibiotic discovery to decrease mortality. However, its
efficacy remains controversial. HIV/AIDS has known link
with tuberculosis but other risk factors have also emerged in
recent years as important determinants of the TB epidemic,
one of which is diabetes mellitus. Risk or new emerging and
re-emerging pathogens originated from animals after having
crossed the species barrier (e.g., Ebola) and re-appearance of
old diseases like pertussis, measles and known limitations of
drugs underline need for innovative vaccines as highly potent
tool to tackle resistance and valuable alternative from long
term perspective being clearly recognized as a major tool for
public health.
ivankahhaluskova@gmail.comVirol Res J 2017, 1:4